Edition:
United Kingdom

Catalent Inc (CTLT.N)

CTLT.N on New York Stock Exchange

53.76USD
17 Jul 2019
Change (% chg)

-- (--)
Prev Close
$53.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
221,578
52-wk High
$55.98
52-wk Low
$29.26

Select another date:

Tue, Jul 16 2019

BRIEF-Catalent Biologics Announces Agreement To Provide Production For Spinal Muscular Atrophy

* CATALENT INC. - CATALENT ANNOUNCES AGREEMENT TO PROVIDE PRODUCTION FOR SPINAL MUSCULAR ATROPHY

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion (916.4 million pounds) in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

UPDATE 3-Catalent seeks slice of gene therapy market with Paragon buy

April 15 Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

Catalent to buy Paragon Bioservices for $1.2 bln

April 15 Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion.

Catalent to buy Paragon Bioservices for $1.2 billion: WSJ

Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

UPDATE 1-Catalent to buy Paragon Bioservices for $1.2 bln -WSJ

April 14 Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

Catalent to buy Paragon Bioservices for $1.2 bln -WSJ

April 14 Drug developer Catalent Inc has agreed to buy privately held Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

Select another date: